Dermatologic Manifestations of Staphylococcal Scalded Skin Syndrome

Back

Background

Staphylococcal scalded skin syndrome (SSSS) is a toxin-mediated exfoliative dermatitis. Toxin-mediated staphylococcal syndromes comprise a group of blistering skin diseases, ranging in severity from localized bullous impetigo to SSSS. SSSS is a systemic toxigenic process producing constitutional symptoms and widespread superficial blistering and exfoliation of the skin following generalized painful erythema.

Pathophysiology

Staphylococcal scalded skin syndrome (SSSS) is caused by toxigenic strains of Staphylococcus aureus, a gram-positive, catalase-positive bacterium. Only 5% of all S aureus strains produce the epidermolytic toxins responsible for SSSS. The specific toxigenic strains usually belong to phage group 2 (types 3A, 3B, 3C, 55, or 71). Two exotoxins (ETs), epidermolytic toxin A (ET-A) and epidermolytic toxin B (ET-B), are responsible for the pathologic changes seen in SSSS.[1] These toxins cause intraepidermal splitting through the granular layer of the epidermis, or stratum granulosum, by specific cleavage of desmoglein 1 (Dsg-1) (also the target protein in the autoimmune blistering dermatosis, pemphigus foliaceus). DSG1 is a desmosomal cadherin protein that mediates cell-to-cell adhesion of keratinocytes in all layers of the epidermis, including the skin and mucosa, but is in greatest abundance within the stratum granulosa. Desmoglein 3 (Dsg-3) (the target protein in the autoimmune blistering dermatosis, pemphigus vulgaris) is also present in the epidermis; it is expressed in the deeper layers of the skin and present in all layers of the mucosa. The distribution of desmogleins in the epidermis explains the preferential blistering of SSSS in the superficial skin and lack of blistering in mucous membranes. Despite cleavage of Dsg-1 by ET-A and ET-B, Dsg-3 maintains the integrity of the deeper layers of the skin, beginning with the stratum spinosum, and all layers of the mucosa.[2, 3, 4]

Specific targeting of Dsg-1 by ETs allows S aureus to proliferate and spread beneath the barrier of the skin. Crystal structures and amino acid sequences indicate that these toxins are calcium-dependent, atypical serine proteases and exhibit substrate specificity for glutamic acid. Therefore, these toxins cleave Dsg-1 at the N-terminus of glutamic acid residue 381 between extracellular domains 3 and 4. The ET-A and ET-B amino acid sequences are approximately 40% identical with each other. ET-A is expressed in more than 80% of toxigenic strains of S aureus and represents the more prevalent ET seen in SSSS. ET-B was found to be the more prevalent toxin in toxigenic strains only in Japan.[5]

An additional ET family member, ET-D, has been identified by screening the genomes of S aureus isolated from patients with skin infections. Studies demonstrated that ET-D specifically digests Dsg-1. However, ET-D is less common in S aureus isolated from SSSS cases and only ET-A and ET-B have been firmly linked to human SSSS. The ET-D gene was detected mainly in isolates from patients with skin and soft-tissue infections, namely furuncles, abscesses, and finger pulp infections.[6, 7]

In addition to the cleavage of Dsg-1, ET-A is correlated with a blunted inflammatory response within the affected superficial skin. While no direct effect by ET-A on white blood cells (WBCs) has been shown, it is hypothesized that Dsg-1 cleavage somehow triggers inhibition of the WBC infiltration of the local environment. Interleukin 6 (IL-6) production and subsequent release by keratinocytes is increased without similar increases in acute, proinflammatory cytokines following Dsg-1 cleavage. Both phenomena contribute to the local modulation of the immune response in SSSS.[8]

It has been suggested that ET-B is more frequently isolated than ET-A in children with SSSS. This link between ET-B and generalized SSSS might be due to increased virulence of ET-B or to more abundant ET-B release. Because ET-A is chromosome borne and ET-B is plasmid borne, multiple intracellular copies of ET-B may exist, which would lead to higher ET-B production. However, levels of ET-A and ET-B are quite similar in vitro. The link between ET-B and generalized SSSS may be explained, at least in part, by lower levels of anti–ET-B antibodies compared with anti–ET-A antibodies in the general population.

The mechanism of neonatal infection is through an asymptomatic adult carrier introducing the causative bacteria into nurseries. Nursery attendants have been identified as the source more commonly than infant mothers. Asymptomatic nasal carriage of S aureus occurs in 20-40% of healthy individuals. The bacterium is also commonly isolated from the hands, perineum, and axillae in a smaller portion of the general population. Common foci of infection in the affected patient include the conjunctivae, periumbilical and perioral regions, nares, and perineum. These sites should be targeted for isolation of S aureus in affected patients.

Epidemiology

Frequency

United States

Staphylococcal scalded skin syndrome (SSSS) most commonly occurs in infants and in young children, and it tends to occur in outbreaks in neonatal nurseries or in daycare nurseries.[9, 10, 11] Large outbreaks of SSSS in neonatal nurseries have been described, but the occurrence of SSSS in adults as a nosocomial infection appears to be exceptional; epidemics have never been observed. Adult infection and disease development are seen in specific instances involving either predisposition to SSSS development, such as HIV infection or chronic kidney disease, or a procedure or trauma that creates a potential nidus for S aureus infection.

Epidemiologic data on strains of S aureus that produce ET are scarce. In a prospective clinical and bacteriologic study, 5.1% of 944 isolates of S aureus were identified as ET producers. SSSS in adults is an exceedingly rare disorder; however, more than 50 cases have been documented.

International

A retrospective study at the Lagos University Teaching Hospital in Nigeria over a 12-year period (January 1995 to December 2006) reviewed the presentation, etiology, and prognosis of nonburn epidermal loss. Only 2 (9%) of 19 patients had confirmed SSSS. The first patient was an 18-day-old boy and the other was a 26-day-old girl admitted with a left lateral thigh abscess. Cultures in both cases yielded the growth of S aureus, which responded well to antibiotic treatment and dressings.[12]

In another retrospective study in England, hospital admissions were reviewed to identify trends in community-onset disease that were likely to be caused by pathogenic staphylococci. Hospital admission rates for staphylococcal septicemia, staphylococcal pneumonia, SSSS, and impetigo increased greater than 5-fold from 1989 through 2004. SSSS was seen primarily in individuals older than 16 years. This reflects the real increases in pathogenic community-onset staphylococcal disease over the past 15 years.[13] An outbreak in a maternity unit in England from December 2012 to March 2013 reinforced the importance of the role of healthcare workers in the nosocomial transmission of the syndrome.[14] A similar outbreak in a maternity unit in Italy from November 2014 to December 2014 identified 3 (4.5%) of 66 infants with SSSS. The infection was traced to methicillin-resistant S aureus (MRSA) colonization of three nurses and one mother. Overall, carriage of S aureus in the nares among the healthcare workers in the maternity unit was 24.1%. This report further supports the prevalence of asymptomatic carriers and their impact in neonatal outbreaks.[15]

Race

Black children are less prone to staphylococcal scalded skin syndrome (SSSS) than white children. This finding could be explained by the greater percentage of white individuals colonized with S aureus within the nasal mucosa compared with all other races. It has been well documented that carriage of S aureus is associated with increased risk of infection. The greater percentage of carriage in the white population may be correlated with the larger number of documented cases of SSSS within this population.[16]

Sex

Staphylococcal scalded skin syndrome occurs equally in both males and females in children. However, a slight male-to-female predominance of 2:1 exists in adults.

Age

Three significant factors determine the age distribution of staphylococcal scalded skin syndrome (SSSS): (1) antibody-mediated immunity to the epidermolytic toxins, (2) renal clearance of the toxins, and (3) general immune status of an individual. Antibodies to ET-A and ET-B develop over time and are seen in older children and adult sera. A lack of specific toxin immunity (antibodies) in neonates is one factor that puts this group at highest risk. Both ET-A and ET-B are cleared by the kidneys; therefore, a decreased ability to achieve renal clearance of toxins puts both neonates and all individuals with chronic kidney disease at a greater risk. Immunodeficiency in adults due to HIV infection, advanced stage of cancer, or numerous comorbid conditions, also increases the risk of SSSS. The immature immune system of the neonate and child also contributes to the prevalence of disease in this population.

Owing to these factors, SSSS most commonly affects children younger than 5 years, particularly neonates. Older children and adults also may develop the disease. Although most cases can be explained by renal insufficiency or immunodeficiency, not all adults have an underlying condition. Infection in healthy adults usually occurs from a massive production of toxins as opposed to the mode of disease in the previously mentioned groups, which occurs through deficiency in toxin elimination. Affected adults range in age from 19-91 years, with half the cases occurring in adults older than 60 years.[17, 18, 19, 20]

Prognosis

The prognosis of the disease in children is favorable, as the mortality rate is less than 5% with appropriate treatment. In adult cases of staphylococcal scalded skin syndrome (SSSS), the mortality rate is high, reaching 60% in some studies, despite appropriate antibiotic therapy.[5]

Children generally do well and are not as ill as their dramatic eruptions might suggest. SSSS is usually associated with a trivial infective focus in the conjunctivae or the skin; however, severe infections, such as sepsis, do contribute to a low but appreciable fatality rate (<10%).<ref>21 </ref>Morbidity in the occasional child who develops cellulitis, sepsis, and pneumonia can be significant. In children, the foci of staphylococcal infections are usually the nasopharynx or localized skin infections.

Adults with SSSS often have blood cultures positive for toxigenic S aureus, and mortality rates can be high (40-63%).[21] The predisposing conditions are renal failure and an immunocompromised state. In older patients, underlying consumptive infectious diseases contribute to the high mortality rates.[22]

SSSS in the adult population has been reported as a complication of septic arthritis after an elective right knee arthroscopy, diffuse large B-cell lymphoma following a right groin biopsy, and lupus nephritis associated with chronic immunosuppressant therapy and renal impairment.[23, 24]

A single report describes concurrent SSSS and toxic shock syndrome (TSS), an acute life-threatening illness caused by TSS toxin also produced by S aureus, in a 43-year-old man associated with an abscess from previous dental work. This patient had normal renal function, but the amount of toxin produced from the abscess may have overwhelmed the kidneys' capacity to remove it. Although colonization with a strain of S aureus capable of producing TSS toxin and ET-A or ET-B is possible, the clinical presentation of both SSSS and TSS is extremely uncommon.[25] Only one other such case has been reported.[26]

History

Staphylococcal scalded skin syndrome (SSSS) originates from a focus of infection that may be a purulent conjunctivitis, otitis media, or occult nasopharyngeal infection. A case of SSSS from a nasal septal abscess, presumably arising from a traumatic hematoma (a tsunami survivor), has been reported, as well as adult infection in a previously healthy man following a dental procedure.[25, 27] In premature infants, a previous amniocentesis procedure and intrauterine infection have been reported as triggers for SSSS, although reports of outbreaks within nurseries is well described and should still be considered in premature infants in addition to all term infants.[28, 29]

Circumcision sites and the umbilicus are other common niduses of infection in the newborn period. SSSS usually begins with fever, irritability, and a generalized, faint, orange-red, macular erythema with cutaneous tenderness. Irritability in children is very commonly reported. Children may complain of vague pain in regions of developing lesions, such as abdominal pain with a superficial abdominal lesion.

SSSS can present with immediate widespread erythema or may begin with a localized site of exudative erythema and rapidly spread, usually within hours. An area of local, painful bullae that remains localized over days is unlikely to be SSSS and is more likely to be bullous impetigo. These lesions should be treated appropriately, but monitored closely as there have been reports of misdiagnosis, missing SSSS completely, and bullous impetigo evolving into SSSS.[30, 31]

Periorificial and flexural accentuation may be observed. A positive Nikolsky sign (separation of the superficial layer of the epithelium on gentle pressure) can often be elicited at this stage.

Physical Examination

Patients usually present with fever and pain associated with a generalized, macular, salmon-colored to bright-red rash, as shown in the image below. Within 24-48 hours, the rash progresses from a scarlatiniform rash to an edematous, blistering eruption.



View Image

An infant with characteristic coloring of the skin that looks as though the child has been scalded. Exfoliation of thin sheets of skin is present.

Characteristic tissue paper–like wrinkling of the epidermis is followed by the appearance of large, flaccid bullae in the axillae, in the groin, and around the body orifices. Perioral involvement is commonly seen in children and adults. Periumbilical and perineal involvement is more common in infants. Extremity involvement is seen more often in older children. The Nikolsky sign, the sloughing of superficial epidermis with gentle shearing force applied to the top of a lesion, is present in staphylococcal scalded skin syndrome (SSSS). See the image below.



View Image

Staphylococcal scalded skin syndrome in an adult.

Subsequent generalized involvement occurs elsewhere on the body, but infection spares the mucous membranes, owing to the presence of unaffected Dsg-3 throughout all strata of the mucosa.

As sheets of epidermis are shed, a moist erythematous base is revealed. Patients experience pain throughout the evolution of the disease owing to the intact free nerve endings terminating in the epidermis. Twenty-four hours following the exfoliation of the skin, the underlying epidermis dries, resulting in a shiny crust. With drying, perioral and periorbital lesions may fissure.

Despite the dramatic clinical picture, the entire process usually subsides with superficial desquamation if antibiotics are administered. Healing is typically rapid, with complete resolution within 5-7 days, although 2-3 weeks is more commonly expected. Children may undergo a second phase of desquamation around day 10, but the disease process still completely resolves around day 14.

In adults, SSSS is frequently followed by bacteremia and pneumonia, favoring a poor prognosis.

Cultures obtained from intact bullae usually are sterile; this finding is consistent with hematogenous dissemination of a toxin produced at a distant focus of staphylococcal infection. Blood cultures usually are negative in infants and children, but commonly positive in adults.

An abortive form of SSSS, known as the scarlatiniform variant, shows the early erythrodermic and final desquamative stages seen in SSSS, but the bullous stage does not occur.

Other intermediate forms of scalded skin syndrome begin as localized bullous impetigo, but they evolve to produce regionally limited bullae and denuded areas that may or may not harbor staphylococci.

Causes

See Pathophysiology.

ET-A and ET-B are atypical glutamic acid–specific serine proteases that specifically target Dsg-1. They are also sources of superantigenic activity and activate macrophages to produce proinflammatory cytokines, such as tumor necrosis factor-alpha and IL-6, and keratinocytes to produce IL-6. ET-A with an active site mutation was shown to possess similar inflammatory activity, indicating that the inflammatory activity of ET-A was separate from its epidermolytic activity, although it has not been shown to directly modulate cytokine release and may likely be due to a downstream effect after Dsg-1 cleavage.[5, 32] The preferential production of IL-6 from keratinocytes in response to ET-A activity results in localized immune dysregulation and lack of a significant WBC infiltrate. Systemic symptoms, particularly the characteristic rash, are very likely a direct result of the toxin.

A small number of patients with staphylococcal scalded skin syndrome (SSSS) develop low titers of immunoglobulin G antibodies specific for Dsg-1 after binding and systemic digestion of Dsg-1 by staphylococcal exfoliative toxins.[33] The relevance of this finding to the onset of autoimmune diseases remains to be proven. Other genetic or environmental factors may be needed to propagate production of pathogenic antibodies and to produce overt clinical pemphigus foliaceus.[34]

Complications

Cellulitis, sepsis, and pneumonia are possible complications that may occur in children with staphylococcal scalded skin syndrome (SSSS). Cellulitis occurs after spreading of the infection to deeper layers of the skin. Dsg-1 is present in the deeper layers of the skin, and while Dsg-3 protects sloughing of the deeper layers, the effects of ET-A and ET-B create a weakened stratum spinosum, leading to the potential for cellulitis. Sepsis is the most serious complication and is the most common cause of mortality in neonates with SSSS.

Dehydration and secondary infection due to loss of the superficial layer of the skin are significant causes of morbidity and are critical issues early on in the disease process. Considerable electrolyte disturbances may ensue if dehydration is not managed at the first sign of disease.

Scarring is not seen in SSSS, owing to the sparing of the deeper layers of the skin.

Laboratory Studies

The definitive diagnosis of staphylococcal scalded skin syndrome (SSSS) depends on culture, biopsy results, and polymerase chain reaction (PCR) of circulating toxin.

Examination of frozen sections of the lesions can easily confirm the diagnosis. Shave or punch biopsy with full-thickness specimens is the recommended technique for biopsy. Painless unroofing of bullae can also provide a reliable sample.[35]

Slide latex agglutination, double immunodiffusion, and enzyme-linked immunosorbent assay tests can identify the toxins responsible for SSSS.

Cultures should be performed in all patients with suspected SSSS for identification and antibiotic sensitivities of the causative organism. S aureus may be cultured from the conjunctiva, nasopharynx, feces, or pyogenic foci on the skin. In neonates, culturing the umbilicus and circumcision site also is critical. Although bullae usually are sterile in SSSS, culturing from likely sources of the focus of infection should result in positive cultures. Blood cultures are almost always negative in children, but they may be positive in adults.[21]

Investigate the possibility of a staphylococcal carrier in the vicinity especially in neonates within a nursery or infants and children in day care centers.

Histologic Findings

All forms of scalded skin syndrome are characterized by intraepidermal, subcorneal cleavage with splitting that occurs beneath and within the stratum granulosum. The cleavage space may contain free-floating or partially attached acantholytic cells. The remainder of the epidermis appears unremarkable, and the dermis contains no inflammatory cells or bacteria.

Medical Care

Direct the therapy for staphylococcal scalded skin syndrome (SSSS) at eradication of the staphylococcal focus of infection, which generally requires intravenous (IV), penicillinase-resistant, antistaphylococcal antibiotics. The empiric choice of antibiotics should include a penicillinase-resistant penicillin, first- or second-generation cephalosporin, and clindamycin. Susceptibility testing should direct changes in antibiotics as soon as results are available.

Oral antibiotic therapy can be substituted within several days or sooner, but initial IV antibiotics should be started in all patients. Corticosteroids should be avoided in SSSS treatment. Antibiotics, supportive care, and appropriate attention to fluid and electrolyte management for the disrupted epidermal barrier function usually ensure rapid recovery. Moist, denuded areas should be lubricated with a bland emollient to decrease pruritus and tenderness. Skin-substitute therapy with synthetic wound coverings has been described in a study with seven infants with SSSS and may be considered if extensive skin involvement is present.[36] Pain management should be considered throughout the disease process. Affected areas should be gently cleansed to avoid secondary infection. Desquamated skin should be left in place as a natural barrier. Lastly, patients should be placed in contact isolation.

Exchange transfusion has been shown to be beneficial in a preterm infant with severe SSSS with sepsis and hyperbilirubinemia, by reducing the bacterial load and exfoliative toxins in the blood.[37]

Plasma exchange was also shown to be effective in a 68-year-old man with sepsis, infective endocarditis, and disseminated intravascular coagulation.[38] In another case report of SSSS in a premature neonate, a single dose of intravenous immunoglobulin (IVIG) was administered at 1 g/kg dose, with clinical improvement occurring within a few days. The presence of antiexfoliative toxin antibodies in commercial IVIG preparations has been reported previously.

Recognizing the potential for epidemic scalded skin syndrome in neonatal care units is important.[39]  Identification of health care workers colonized or infected with toxigenic S aureus is an integral part of managing the problem. Receiving more than one early umbilical care procedure by the same ancillary nurse was the only risk factor identified in a nosocomial outbreak in a maternity unit in France. The ancillary nurse had chronic dermatitis on her hands that favored S aureus carriage.[40] Control measures include strict enforcement of chlorhexidine hand washing, barrier nursing protocols, administration of an oral antibiotic therapy for workers who are infected, and application of mupirocin ointment for eradication of persistent nasal carriage.

Further inpatient care

Developments in the understanding of the exfoliative toxins of SSSS should lead to new and improved diagnostic and therapeutic strategies, including the use of specific antitoxins to prevent exfoliation.[41]

Infusing anti-ET antibodies into mice was shown to halt progression of exfoliation in a study performed more than 2 decades ago, but this has never been applied to humans.

A recent surge has occurred in reports of MRSA strains causing SSSS, often with a fatal outcome. Additionally, a multiple-drug resistance gene has been identified on plasmids carrying the ET-B gene. These cases emphasize the need to develop alternative treatment strategies before multiple antibiotic resistance becomes a problem.

Animal model studies have demonstrated that subinhibitory concentrations of antibiotics such as clindamycin can significantly inhibit toxin production by methicillin-sensitive and methicillin-resistant staphylococcal strains, and anti-inflammatory agents such as pentoxifylline can further inhibit activation of the body's inflammatory response to these toxins. Currently, little clinical evidence supports their routine use in the management of SSSS.

Prevention of progression of SSSS by molluscum contagiosum has been observed and indicates possible interference by a viral anticytokine molecule, such as interleukin 18–binding protein. The development of drugs based on inflammatory cytokines, including interleukin 18, may be invaluable for halting the progression of severe cases.[42]

Consultations

Children with severe staphylococcal scalded skin syndrome (SSSS) (>50% body surface area) may need to be transferred to a tertiary pediatric burn unit for multidisciplinary care in a critical care environment.

A dermatologist is often consulted to provide management guidance and direct wound care.

Fluid overload and hyponatremia are common complications of SSSS. This is not surprising because hyponatremia is common in severe infections and inappropriate vasopressin secretion occurs in patients with burns. Rapid fluid resuscitation also contributes to this complication and should be avoided.[43]

For treatment of toxemia in children, fresh frozen plasma (FFP) at 10 mL/kg may be beneficial, as it contains exotoxin antibodies. If a second dose is required, it should come from a different donor because the possibility exists that the first donor did not have antibodies against the epidermolytic toxins. A 5-day course of pooled human immunoglobulin (0.4 g/kg/d) should also be considered if little or no improvement is noted after two doses of FFP.

Many children require an opioid infusion, such as fentanyl (1-4 mcg/kg/h), for analgesia. Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in the acute phase because the damaged skin is already prone to bleeding and renal excretion of the exotoxins makes maximized renal function important. Gabapentin is useful for severe pruritus (100 mg/kg once on day 1, twice a day on day 2, and then three times each day) and may need to be continued for a few months.

Diet

Enteral nutrition must be commenced if oral intake is not possible. This may be achieved with a nasogastric tube, but a nasojejunal tube is preferable because it avoids the need to discontinue feeds prior to anesthesia. Nasojejunal (or nasogastric) tubes are likely to require suturing into place to avoid epidermal damage from adhesives.

Activity

Physiotherapy is important to encourage mobilization in general, and specifically of the affected limbs. Because staphylococcal scalded skin syndrome tends to affect the flexures most severely, children often limit flexion of the limbs owing to discomfort, and physiotherapy is very helpful in preventing this. Involvement of play therapists also helps encourage gentle mobilization and prevents boredom.

Prevention

Investigate the possibility of a staphylococcal carrier in the vicinity. Typical measures that reduce infection rates in hospitals should be take,n including regular hand washing, cleansing stethoscopes or other devices between each patient interaction, and ensuring proper cleansing of linens and clothing.

Nasal bacterial carriage or colonization under fingernails can be minimized with antibiotic creams or petroleum jelly several times daily, 1 week per month.

Medication Summary

The goal of pharmacotherapy for staphylococcal scalded skin syndrome (SSSS) is to reduce morbidity and to prevent complications.[44, 45]

Dicloxacillin (Dycill, Dynapen)

Clinical Context:  Dicloxacillin is for the treatment of infections caused by penicillinase-producing staphylococci. It should be used as empiric therapy in combination with clindamycin when staphylococcal infection is suspected and susceptibilities are pending.

Clindamycin (Cleocin, Cleocin Pediatric, ClindaMax Vaginal)

Clinical Context:  Clindamycin is a bacteriostatic protein synthesis inhibitor that has efficacy in treating MRSA. It should be used as empiric therapy in combination with a penicillinase-resistant penicillin when staphylococcal infection is suspected and susceptibilities are pending.

Mupirocin (Bactroban)

Clinical Context:  Mupirocin inhibits bacterial growth by inhibiting RNA and protein synthesis and should be used only at the site of S aureus infection. 

Class Summary

Empiric antimicrobial therapy must be comprehensive and should cover all likely pathogens in the context of the clinical setting. The empiric antibiotic regime should include a penicillinase-resistant penicillin and clindamycin. First- or second-generation cephalosporins can be used in place of penicillins.

Author

Elizabeth J Usedom, MD, MS, Resident Physician, Department of Dermatology, Wright State University, Boonshoft School of Medicine

Disclosure: Nothing to disclose.

Coauthor(s)

Amanda T Moon, MD, Clinical Assistant Professor of Dermatology, Children's Hospital of Philadelphia

Disclosure: Nothing to disclose.

Specialty Editors

Michael J Wells, MD, FAAD, Dermatologic/Mohs Surgeon, The Surgery Center at Plano Dermatology

Disclosure: Nothing to disclose.

Edward F Chan, MD, Clinical Assistant Professor, Department of Dermatology, University of Pennsylvania School of Medicine

Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD, Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Disclosure: Nothing to disclose.

Additional Contributors

Leonard Sperling, MD, Chair, Professor, Department of Dermatology, Uniformed Services University of the Health Sciences

Disclosure: Nothing to disclose.

Paul Benson, MD, Chief, Program Director, Dermatology Service, Walter Reed Army Medical Center; Associate Professor, Department of Dermatology, Uniformed Services University of the Health Sciences at Bethesda

Disclosure: Nothing to disclose.

Acknowledgements

Jessica H Kim, MD Clinical Assistant Professor, Division of Dermatology, University of Washington School of Medicine; Dermatology Consultant, Cascade Eye & Skin Centers

Jessica H Kim, MD is a member of the following medical societies: American Academy of Dermatology, American Contact Dermatitis Society, American Society for Dermatologic Surgery, American Society for Laser Medicine and Surgery, National Psoriasis Foundation, Washington State Medical Association, and Women's Dermatologic Society

Disclosure: Nothing to disclose.

References

  1. Ladhani S, Robbie S, Garratt RC, Chapple DS, Joannou CL, Evans RW. Development and evaluation of detection systems for staphylococcal exfoliative toxin A responsible for scalded-skin syndrome. J Clin Microbiol. 2001 Jun. 39(6):2050-4. [View Abstract]
  2. Amagai M. Desmoglein as a target in autoimmunity and infection. J Am Acad Dermatol. 2003 Feb. 48(2):244-52. [View Abstract]
  3. Anzai H, Stanley JR, Amagai M. Production of low titers of anti-desmoglein 1 IgG autoantibodies in some patients with staphylococcal scalded skin syndrome. J Invest Dermatol. 2006 Sep. 126(9):2139-41. [View Abstract]
  4. Hanakawa Y, Stanley JR. Mechanisms of blister formation by staphylococcal toxins. J Biochem (Tokyo). 2004 Dec. 136(6):747-50. [View Abstract]
  5. Bukowski M, Wladyka B, Dubin G. Exfoliative toxins of Staphylococcus aureus. Toxins (Basel). 2010 May. 2 (5):1148-65. [View Abstract]
  6. Yamasaki O, Tristan A, Yamaguchi T, et al. Distribution of the exfoliative toxin D gene in clinical Staphylococcus aureus isolates in France. Clin Microbiol Infect. 2006 Jun. 12(6):585-8. [View Abstract]
  7. Yamasaki O, Yamaguchi T, Sugai M, et al. Clinical manifestations of staphylococcal scalded-skin syndrome depend on serotypes of exfoliative toxins. J Clin Microbiol. 2005 Apr. 43(4):1890-3. [View Abstract]
  8. Rolle CE, Chen J, Pastar I, Cardenas TC, Perez R, Hower S, et al. Keratinocytes produce IL-6 in response to desmoglein 1 cleavage by Staphylococcus aureus exfoliative toxin A. Immunol Res. 2013 Dec. 57 (1-3):258-67. [View Abstract]
  9. Mishra AK, Yadav P, Mishra A. A Systemic Review on Staphylococcal Scalded Skin Syndrome (SSSS): A Rare and Critical Disease of Neonates. Open Microbiol J. 2016. 10:150-159. [View Abstract]
  10. Hennigan K, Riley C. Staphylococcal Scalded Skin Syndrome: A Case Review. Neonatal Netw. 2016. 35 (1):8-12. [View Abstract]
  11. Kouakou K, Dainguy ME, Kassi K. Staphylococcal Scalded Skin Syndrome in Neonate. Case Rep Dermatol Med. 2015. 2015:901968. [View Abstract]
  12. Ugburo AO, Temiye EO, Ilombu CA. A 12-year retrospective study of non-burn skin loss (burn-like syndromes) at a tertiary burn unit in a developing country. Burns. 2008. 34:637-643. [View Abstract]
  13. Hayward A, Knott F, Petersen I, et al. Increasing hospitalizations and general practice prescriptions for community-onset staphylococcal disease, England. Emer Infect Dis. May 2008. 14(5):720-6. [View Abstract]
  14. Paranthaman K, Bentley A, Milne LM, Kearns A, Loader S, Thomas A, et al. Nosocomial outbreak of staphyloccocal scalded skin syndrome in neonates in England, December 2012 to March 2013. Euro Surveill. 2014 Aug 21. 19(33):[View Abstract]
  15. Lamanna O, Bongiorno D, Bertoncello L, Grandesso S, Mazzucato S, Pozzan GB, et al. Rapid containment of nosocomial transmission of a rare community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) clone, responsible for the Staphylococcal Scalded Skin Syndrome (SSSS). Ital J Pediatr. 2017 Jan 6. 43 (1):5. [View Abstract]
  16. Cole AM, Tahk S, Oren A, Yoshioka D, Kim YH, Park A, et al. Determinants of Staphylococcus aureus nasal carriage. Clin Diagn Lab Immunol. 2001 Nov. 8 (6):1064-9. [View Abstract]
  17. Cribier B, Piemont Y, Grosshans E. Staphylococcal scalded skin syndrome in adults. A clinical review illustrated with a new case. J Am Acad Dermatol. 1994 Feb. 30(2 Pt 2):319-24. [View Abstract]
  18. Dobson CM, King CM. Adult staphylococcal scalded skin syndrome: histological pitfalls and new diagnostic perspectives. Br J Dermatol. 2003 May. 148(5):1068-9. [View Abstract]
  19. Hardwick N, Parry CM, Sharpe GR. Staphylococcal scalded skin syndrome in an adult. Influence of immune and renal factors. Br J Dermatol. 1995 Mar. 132(3):468-71. [View Abstract]
  20. Mockenhaupt M, Idzko M, Grosber M, Schopf E, Norgauer J. Epidemiology of staphylococcal scalded skin syndrome in Germany. J Invest Dermatol. 2005 Apr. 124(4):700-3. [View Abstract]
  21. Handler MZ, Schwartz RA. Staphylococcal scalded skin syndrome: diagnosis and management in children and adults. J Eur Acad Dermatol Venereol. 2014 May 20. [View Abstract]
  22. Patel GK, Finlay AY. Staphylococcal scalded skin syndrome: diagnosis and management. Am J Clin Dermatol. 2003. 4(3):165-75. [View Abstract]
  23. Miyashita K, Ogawa K, Iioka H, Miyagawa F, Okazaki A, Kobayashi N, et al. Adult case of staphylococcal scalded skin syndrome differentiated from toxic epidermal necrolysis with the aid of dermoscopy. J Dermatol. 2016 Jul. 43 (7):842-3. [View Abstract]
  24. Rydzewska-Rosolowska A, Brzosko S, Borawski J, Mysliwiec M. Staphylococcal scalded skin syndrome in the course of lupus nephritis. Nephrology (Carlton). Jun 2008. 13(3):265-6. [View Abstract]
  25. Brewer JD, Hundley MD, Meves A, Hargreaves J, McEvoy MT, Pittelkow MR. Staphylococcal scalded skin syndrome and toxic shock syndrome after tooth extraction. J Am Acad Dermatol. Aug 2008. 59(2):342-6. [View Abstract]
  26. Toyota E, Mitake H, Mikami Y, et al. A case of TSS complicated with SSSS in an adult with liver cirrhosis (in Japanese). Kansenshogaku Zasshi. 1994. 68:1421-7.
  27. Adhisivam B, Mahadevan S. Abscess of the nasal septum with staphylococcal scalded skin syndrome. Indian Pediatr. 2006 Apr. 43(4):372-3. [View Abstract]
  28. Haveman LM, Fleer A, de Vries LS, Gerards LJ. Congenital staphylococcal scalded skin syndrome in a premature infant. Acta Paediatr. 2004 Dec. 93(12):1661-2. [View Abstract]
  29. Kapoor V, Travadi J, Braye S. Staphylococcal scalded skin syndrome in an extremely premature neonate: a case report with a brief review of literature. J Paediatr Child Health. Jun 2008. 44(6):374-6. [View Abstract]
  30. Aydin D, Alsbjørn B. Severe case of staphylococcal scalded skin syndrome in a 5-year-old child - case report. Clin Case Rep. 2016 Apr. 4 (4):416-9. [View Abstract]
  31. Bae SH, Lee JB, Kim SJ, Lee SC, Won YH, Yun SJ. Case of bullous impetigo with enormous bulla developing into staphylococcal scalded skin syndrome. J Dermatol. 2016 Apr. 43 (4):459-60. [View Abstract]
  32. Takagi Y, Futamura S, Asada Y. Action site of exfoliative toxin on keratinocyte. J Invest Dermatol. 1990. 94:582.
  33. Saida K, Kawasaki K, Hirabayashi K, Akazawa Y, Kubota S, Kasuga E, et al. Exfoliative toxin A staphylococcal scalded skin syndrome in preterm infants. Eur J Pediatr. 2014 Sep 7. [View Abstract]
  34. Stanley JR, Amagai M. Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome. N Engl J Med. 2006 Oct 26. 355(17):1800-10. [View Abstract]
  35. Elston DM, Stratman EJ, Miller SJ. Skin biopsy: Biopsy issues in specific diseases. J Am Acad Dermatol. 2016 Jan. 74 (1):1-16; quiz 17-8. [View Abstract]
  36. Baartmans MG, Dokter J, den Hollander JC, Kroon AA, Oranje AP. Use of skin substitute dressings in the treatment of staphylococcal scalded skin syndrome in neonates and young infants. Neonatology. 2011. 100 (1):9-13. [View Abstract]
  37. Tenenbaum T, Hoehn T, Hadzik B, et al. Exchange transfusion in a preterm infant with hyperbilirubinemia, staphylococcal scalded skin syndrome (SSSS) and sepsis. Eur J Pediatr. Jul 2007. 166(7):733-5. [View Abstract]
  38. Kato T, Fujimoto N, Nakanishi G, Tsujita Y, Matsumura K, Eguchi Y, et al. Adult staphylococcal scalded skin syndrome successfully treated with plasma exchange. Acta Derm Venereol. 2015 May. 95 (5):612-3. [View Abstract]
  39. Neylon O, O'Connell NH, Slevin B, Powell J, Monahan R, Boyle L, et al. Neonatal staphylococcal scalded skin syndrome: clinical and outbreak containment review. Eur J Pediatr. 2010 Dec. 169(12):1503-9. [View Abstract]
  40. El Helali N, Carbonne A, Naas T, et al. Nosocomial outbreak of staphylococcal scalded skin syndrome in neonates: epidemiological investigation and control. J Hosp Infect. 2005 Oct. 61(2):130-8. [View Abstract]
  41. Ladhani S. Recent developments in staphylococcal scalded skin syndrome. Clin Microbiol Infect. 2001 Jun. 7(6):301-7. [View Abstract]
  42. Kato Z, Tsubouchi K, Kondo N. Molluscum contagiosum prevents progression of staphylococcal scalded skin syndrome. Eur J Pediatr. 2005 Dec. 164(12):768-9. [View Abstract]
  43. Blyth M, Estela C, Young AE. Severe staphylococcal scalded skin syndrome in children. Burns. Feb 2008. 34(1):98-103. [View Abstract]
  44. Ramos-e-Silva M, Pereira AL. Life-threatening eruptions due to infectious agents. Clin Dermatol. 2005 Mar-Apr. 23(2):148-56. [View Abstract]
  45. Reddy K, Kogan S, Glick SA. Procedures and drugs in pediatric dermatology: iatrogenic risks and situations of concern. Clin Dermatol. 2011 Nov-Dec. 29(6):633-43. [View Abstract]

An infant with characteristic coloring of the skin that looks as though the child has been scalded. Exfoliation of thin sheets of skin is present.

Staphylococcal scalded skin syndrome in an adult.

An infant with characteristic coloring of the skin that looks as though the child has been scalded. Exfoliation of thin sheets of skin is present.

Staphylococcal scalded skin syndrome in an adult.